Full Press Release Details
CRISPR Therapeutics to Present New Data on Allogeneic CRISPR-based CAR-T Program and Host Investor
Reception at the 32nd Annual Society for Immunotherapy of Cancer Meeting
ZUG, Switzerland and
CAMBRIDGE, Mass., November 7, 2017 CRISPR Therapeutics (NASDAQ: CRSP), a genome editing company focused on creating transformative medicine for serious diseases, today announced that the Company will present a poster on CRISPR s
Allogeneic CRISPR-based CAR-T cell therapy directed at CD19-positive malignancies at the 32nd Annual Society for Immunotherapy of Cancer Meeting.
Therapeutics will also host an investor reception to highlight its immune-oncology research and development strategy. The program will include a talk by Stephan A. Grupp, MD, PhD., Director of the Cancer Immunotherapy Program, director of
Translational Research for the Center for Childhood Cancer Research at Children s Hospital of Philadelphia and medical director of the Stem Cell Laboratory, Chief of the Section of Cellular Therapy and Transplant in the Hospital s Division
of Oncology, and members from CRISPR s senior management team. For more information on the investor event, please contact IR@crisprtx.com.
Title: Production of site-specific Allogeneic CD19 CAR-T Cells by CRISPR-Cas9 for B-Cell Malignancies
Location: P181, Cellular Therapy Approaches Track
Date: Friday November 10, 2017
CRISPR Therapeutics Investor Reception
Location: Gaylord Hotel at the Gaylord National Resort & Convention Center
Date: Friday November 10, 2017
Guest Speaker: Stephan A. Grupp, MD, PhD, Director of the Cancer Immunotherapy Program, director of Translational Research for
the Center for Childhood Cancer Research at Children s Hospital of Philadelphia and medical director of the Stem Cell Laboratory, Chief of the Section of Cellular Therapy and Transplant in the Hospital s Division of Oncology
A live webcast of the presentation, and the presentation materials, can be accessed under Events & Presentations in the
Investors & Media section of the Company s website at www.crisprtx.com.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious
diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company s multi-disciplinary team of world-class researchers and drug
developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop
CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company s scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is
headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com.
WCG on behalf of CRISPR
+1 347-658-8290 jpaganelli@wcgworld.com
Westwicke Partners for CRISPR